Health Insurance Innovations Inc. would need to rise by more than 200% to reach its mean one-year price target, but with sell-side analysts unanimously in favor of buying the stock, it may have a lot of room to run.
According to an S&P Global Market Intelligence analysis, the health insurance broker had an implied upside of 204.7% as of Aug. 30. Currently, all eight analysts covering Health Insurance Innovations have buy recommendations on its stock, which has struggled lately, losing more than 40% from the end of May through Aug. 31.
Looking out more broadly, 54 of the 61 public U.S. insurance companies included in this analysis were trading below sell-side analysts' mean one-year price targets as of Aug. 30. Five companies had more than 40% of upside potential.
Trupanion Inc. had the second-largest implied upside at 57.7%, and Centene Corp. had the third-largest implied upside at 55.6%.
At the other end of the spectrum, W. R. Berkley Corp. was trading 11.7% above its mean one-year price target at Aug. 30, the most of any insurance underwriter or broker in this analysis. Cincinnati Financial Corp. and RLI Corp., were also trading at least 5% above analysts' mean price targets.
S&P Global Market Intelligence examined U.S. securities and investment companies trading on major exchanges in relation to their mean one-year price targets as of Aug. 30. Only stocks with three or more analyst price targets that were less than a year old and were trading above $5 per share were included in this analysis.

